Yamanouchi Pharmaceutical Company Ltd.

Soichi Kagami

Masuo Murakami

Kozo Takahashi

Takashi Fujikura

Kunihiro Niigata

Toshinari Tamura

Shin-ichi Tsukamoto

Tadao Kojima

Hidenori Iwamoto

Shinji Usuda

Shiro Tachikawa

Minoru Yamamoto

Makoto Yoshida

Yoshihisa Nozaki

Yuji Kawashima

Shin-Ichi Tsukamoto

Substituted azetidinone compounds are provided which have the formula: ##STR1## wherein one of R.sup.1 and R.sup.2 represents a substituted lower alkyl group, an azido group, an amino group, a lower acylamino group, a mercapto group or a lower alkylthio group and the other represents a hydrogen group, or, both represent hydrogen atoms or lower alkyl groups; R.sup.3 represents a hydrogen atom or a group shown by formula: ##STR2## (wherein X represents ##STR3## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group) and Y represents a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group); R.sup.4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a group shown by formula: --CH.sub.2 CO--A (wherein A represents an amino group or a group shown by formula: ##STR4## (wherein X and Y are as defined above), provided that when R.sup.1 and R.sup.2 are both hydrogen atoms, at least R.sup.4 represents a group other than a hydrogen atom and provided that either R.sup.3 or R.sup.4 represents a group other than a hydrogen atom. The compounds have strong CNS action.

CNS active substituted azetidinone compounds

2-(Indenyloxymethyl) morpholine derivatives are disclosed. These derivatives are excellent in methamphetamine stereotyped increasing and antireserpine activities which are useful as antidepression agents.

2-(Indenyloxymethyl) morpholine derivatives

Growing community of inventors

Kawaguchi, Japan

Soichi Kagami